Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients

Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an “off-label” option in pediatric oncology. It has been previously re...

Descripción completa

Detalles Bibliográficos
Autores principales: Rihacek, Michal, Selingerova, Iveta, Kocak, Ivo, Kocakova, Ilona, Rihackova, Eva, Valik, Dalibor, Sterba, Jaroslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221843/
https://www.ncbi.nlm.nih.gov/pubmed/35735439
http://dx.doi.org/10.3390/curroncol29060330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221843/
https://www.ncbi.nlm.nih.gov/pubmed/35735439
http://dx.doi.org/10.3390/curroncol29060330

Ejemplares similares